HbA1c Variability as an Independent Correlate of Nephropathy, but Not Retinopathy, in Patients With Type 2 Diabetes

OBJECTIVE To examine the association of hemoglobin (Hb) A1c variability with microvascular complications in the large cohort of subjects with type 2 diabetes from the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicenter Study. RESEARCH DESIGN AND METHODS Serial (3–5) HbA1c values collected in a 2-year period before enrollment were available from 8,260 subjects from 9 centers (of 15,773 patients from 19 centers). HbA1c variability was measured as the intraindividual SD of 4.52 ± 0.76 values. Diabetic retinopathy (DR) was assessed by dilated funduscopy. Chronic kidney disease (CKD) was defined based on albuminuria, as measured by immunonephelometry or immunoturbidimetry, and estimated glomerular filtration rate (eGFR) was calculated from serum creatinine. RESULTS Median and interquartile range of average HbA1c (HbA1c-MEAN) and HbA1c-SD were 7.57% (6.86–8.38) and 0.46% (0.29–0.74), respectively. The highest prevalence of microalbuminuria, macroalbuminuria, reduced eGFR, albuminuric CKD phenotypes, and advanced DR was observed when both HbA1c parameters were above the median and the lowest when both were below the median. Logistic regression analyses showed that HbA1c-SD adds to HbA1c-MEAN as an independent correlate of microalbuminuria and stages 1–2 CKD and is an independent predictor of macroalbuminuria, reduced eGFR, and stages 3–5 albuminuric CKD, whereas HbA1c-MEAN is not. The opposite was found for DR, whereas neither HbA1c-MEAN nor HbA1c-SD affected nonalbuminuric CKD. CONCLUSIONS In patients with type 2 diabetes, HbA1c variability affects (albuminuric) CKD more than average HbA1c, whereas only the latter parameter affects DR, thus suggesting a variable effect of these measures on microvascular complications.

[1]  A. Levey,et al.  A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.

[2]  P. Home Contributions of basal and post-prandial hyperglycaemia to micro- and macrovascular complications in people with type 2 diabetes , 2005, Current medical research and opinion.

[3]  A. Rigby,et al.  A1C Variability and the Risk of Microvascular Complications in Type 1 Diabetes , 2008, Diabetes Care.

[4]  P. Wilson,et al.  Effects of Prandial Versus Fasting Glycemia on Cardiovascular Outcomes in Type 2 Diabetes: The HEART2D trial , 2009, Diabetes Care.

[5]  A. Rigby,et al.  Glucose variability does not contribute to the development of peripheral and autonomic neuropathy in type 1 diabetes: data from the DCCT , 2009, Diabetologia.

[6]  S. Shin,et al.  HbA1c variability is associated with microalbuminuria development in type 2 diabetes: a 7-year prospective cohort study , 2012, Diabetologia.

[7]  Mark Woodward,et al.  Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. , 2009, Journal of the American Society of Nephrology : JASN.

[8]  D. Dunger,et al.  A1C Variability as an Independent Risk Factor for Microalbuminuria in Young People With Type 1 Diabetes , 2011, Diabetes Care.

[9]  Merlin C. Thomas,et al.  Nonalbuminuric Renal Impairment in Type 2 Diabetic Patients and in the General Population (National Evaluation of the Frequency of Renal Impairment cO-existing with NIDDM [NEFRON] 11) , 2009, Diabetes Care.

[10]  G. Davı̀,et al.  In vivo formation of 8-iso-prostaglandin f2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. , 1999, Circulation.

[11]  R. Poveda,et al.  Goodpasture syndrome during the course of a Schönlein-Henoch purpura. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[12]  L. Laviola,et al.  Rate and Determinants of Association Between Advanced Retinopathy and Chronic Kidney Disease in Patients With Type 2 Diabetes , 2012, Diabetes Care.

[13]  S. Kashyap,et al.  Metabolic syndrome and kidney disease: a systematic review and meta-analysis. , 2011, Clinical journal of the American Society of Nephrology : CJASN.

[14]  E. Bonora,et al.  Diverging Association of Reduced Glomerular Filtration Rate and Albuminuria With Coronary and Noncoronary Events in Patients With Type 2 Diabetes , 2011, Diabetes Care.

[15]  A. Rigby,et al.  Effect of Glucose Variability on the Long-Term Risk of Microvascular Complications in Type 1 Diabetes , 2009, Diabetes Care.

[16]  B. Zinman,et al.  Effect of Glycemic Exposure on the Risk of Microvascular Complications in the Diabetes Control and Complications Trial—Revisited , 2008, Diabetes.

[17]  Matthew D. Davis,et al.  Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. , 2002, JAMA.

[18]  Ethan M Balk,et al.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[19]  E. Kilpatrick,et al.  The rise and fall of HbA1c as a risk marker for diabetes complications , 2012, Diabetologia.

[20]  F. Santilli,et al.  Thromboxane-dependent CD40 ligand release in type 2 diabetes mellitus. , 2006, Journal of the American College of Cardiology.

[21]  E. Bonora,et al.  The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation provides a better definition of cardiovascular burden associated with CKD than the Modification of Diet in Renal Disease (MDRD) Study formula in subjects with type 2 diabetes. , 2011, Atherosclerosis.

[22]  Michael Brownlee,et al.  The Effect of Glucose Variability on the Risk of Microvascular Complications in Type 1 Diabetes , 2007, Diabetes Care.

[23]  E. Bonora,et al.  Clinical significance of nonalbuminuric renal impairment in type 2 diabetes , 2011, Journal of hypertension.

[24]  H. Sone,et al.  HbA1c variability and the development of microalbuminuria in type 2 diabetes: Tsukuba Kawai Diabetes Registry 2 , 2012, Diabetologia.

[25]  R. Holman,et al.  Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study , 2000, BMJ : British Medical Journal.

[26]  Kdoqi Disclaimer K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[27]  Jean-Paul Cristol,et al.  Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. , 2006, JAMA.

[28]  A. Ceriello Hypothesis: the "metabolic memory", the new challenge of diabetes. , 2009, Diabetes research and clinical practice.

[29]  D. Gordin,et al.  A1C Variability Predicts Incident Cardiovascular Events, Microalbuminuria, and Overt Diabetic Nephropathy in Patients With Type 1 Diabetes , 2009, Diabetes.

[30]  D. Gordin,et al.  A 1 C variability predicts incident cardiovascular events , microalbuminuria , and overt diabetic nephropathy in patients with type 1 diabetes , 2009 .

[31]  Matthew D. Davis,et al.  Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. , 2003, Ophthalmology.

[32]  Rury R Holman,et al.  Risk Factors for Renal Dysfunction in Type 2 Diabetes , 2006, Diabetes.

[33]  A. Nicolucci,et al.  Reproducibility of albuminuria in type 2 diabetic subjects. Findings from the Renal Insufficiency And Cardiovascular Events (RIACE) study. , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[34]  G. Davı̀,et al.  In Vivo Formation of 8-Iso-Prostaglandin F2α and Platelet Activation in Diabetes Mellitus , 1999 .